Archive for the ‘professional activism’ Tag
A few years ago, the New York Times reported a strange scheduling phenomenon encountered by patients at dermatology clinics in southern California. The article cited a study in the Journal of the American Academy of Dermatology that examined scheduling wait times in a number of American cities. If a patient were looking for a chemical peel or Botox® injection, clinics could routinely schedule the patient for later the same week. In contrast, if a patient had a concerning mole or eczema that had not responded to routine treatment, it would often take a month to get an appointment. Interviews with industry experts at the time suggested that many dermatology practices were effectively running two separate practices split along patients needing medical versus cosmetic dermatological consultations. “Medical dermatology” is a category within the specialty that addresses dermatological disease (e.g., skin cancer, acne, eczema, psoriasis). “Cosmetic dermatology” refers to dermatologic needs to improve one’s appearance but are not the result of any derangement within the body. Common problems in cosmetic dermatology include wrinkle-reduction, altering skin pigmentation, and removing age spots.
An important aspect of this distinction between the two major categories of dermatologic needs is the grossly different financial impact of each. Cosmetic dermatology is almost never reimbursed by medical insurance while medical dermatology is usually required by law to be included in insurance coverage. This difference effectively creates two classes of patients in a typical dermatology practice. The medical dermatology patients pay a nominal co-pay and then a physician could spend weeks trying to capture a relatively small amount of additional revenue from the patient’s insurance company. In contrast, cosmetic dermatology patients are paying in full at the time of their visit at a price that can theoretically be as high as the local market will bear. The New York Times article noted that a dermatologist could double his or her annual income by focusing more of their practice on cosmetic procedures. The reported scheduling behavior suggests that many dermatology practices attempt to capture a greater share of cosmetic dermatology while potentially limiting the volume of medical dermatology because of these financial incentives.
While the reader’s knee-jerk reaction may be that government regulation be used to “force” dermatologists to more equitably accept both types of patients, I would suggest that the current situation highlights an opportune moment for professional activism of a kind rarely seen in medicine. The ultimate obstacle to scheduling a medical dermatology appointment is a limited supply of appointment slots in certain localities. Ironically, this long-time shortage of medical dermatology care notwithstanding, clinical training in dermatology is one of the most competitive specialties in medicine within which to receive a training position. In theory, if enough dermatologists were trained and sent to practice in an area this shortage would solve itself. However, increasing the number of dermatologists being trained would likely create a disproportionate amount of cosmetic dermatology practices. This disproportionate desire from graduates to practice cosmetic dermatology limits the profession’s desire to expand the number of trainees each year. One potential solution is for a formal distinction in training to be made from cosmetic and medical dermatology. Doing so would not be easy and would likely require a combined effort from accreditation bodies to require the trainees in dermatology only be trained in either subspecialty, and it would also require cooperative state medical boards to prohibit one group practicing the other’s trade. Given the different financial incentives of each subspecialty, a likely result of such a change would be that cosmetic dermatology would continue to be the highly-competitive, highly-compensated field that dermatology largely resembles today while medical dermatology would be a more academically-focused, less competitive, moderately-compensated field that it should be.
The real take away from this discussion is not determining whether the greater dermatology community ever makes such a radical step to fix a distorting externality of the profession. The ultimate point here is that the medical profession, its accrediting bodies, and training institutions ultimately have many of the tools to improve healthcare delivery and training in the U.S. today. Historically, our profession has been relatively passive which encourages external actors (e.g., governments, industry) to shape how we provide care to patients. While engaging outside influencers is important, medical providers are often best suited to recognize and adapt to problems that arise in the practice of medicine. It is up to medical providers then to embrace their role as change-makers.
This post is proceeded by a short case vignette to help frame the discussion that follows.
An 85 year-old man is brought to the hospital with a fever and found to have pneumonia. The man had been diagnosed about six months ago with an incurable form of leukemia, a cancer of the bone marrow. Because of his age and medical history, his pneumonia quickly leads to respiratory failure and he is admitted to an ICU for mechanical ventilation and other critical life-sustaining measures. Over the next few weeks, the patient’s overall condition failed to improve and he suffered a number of further physiologic insults. He became anemic and was transfused two units of blood. The patient then got a bladder infection that resulted in sepsis which caused the patient to cardiac arrest before being successfully resuscitated. After all of these events and the patient’s stable but poor condition, the medical team faced a difficult situation where the patient was too sick to be transferred to a long-term acute care facility but also had little chance of significant improvement. Given the current findings and poor prognosis, the medical team asked the family to reconsider the patient’s status as a “full code,” requiring all life-sustaining measures in the event of further cardiac or respiratory failure. The family felt very strongly that “ALL” medical efforts should be afforded to the patient and refused the medical team’s request. An ethics consultation was called by the primary team.
It is estimated that better management – meaning less aggressive – of patients’ care in the last six months of their life could save $700 billion of U.S. healthcare spending, one-third of the total annual spending on healthcare. Currently, the irreconcilable differences around end-of-life decision-making problems outlined above are handled by hospitals with the use of “ethics consultations.” An ethics consultation typically triggers a review of a patient’s case by a member of the hospital’s ethics committee who has been trained to use the four principles of medical ethics to reframe a particular ethical problem and provide a recommendation for moving forward. For example, in the case above an ethics committee member would highlight the balance that must be struck between the patient’s (and family’s) autonomy to make their own medical decisions versus the continued use of limited healthcare resources on a patient who will never be independently functional and suffering a series of interventions that are likely only prolonging the patient’s guaranteed death from his cancer. The intended purpose of such an exercise is that reframing the discussion in a more analytical manner may help the family or the medical team better understand the other side and highlight a potential resolution.
However, the major limitation of the ethics consultation is that its recommendations are not legally binding and therefore truly irreconcilable differences can rarely be solved by the process. When some form of cooperative agreement cannot be reached, the ethics committee has no power to enforce a recommendation on either party. Published reviews of the history of end-of-life care and medical ethics have highlighted the limited legal protection for either hospitals or patients with end-of-life care as a major hindrance to the available options for resolving these differences of opinion. Without strict legal guidance, hospitals have been forced to utilize a quasi-legal “fair process” system when faced with patients and decision-making surrogates who insist on continued care that has become medically futile. Fair process for withdrawal of care involves an onerous series of consultative steps that requires a medical team to explore alternative care options that include cross-specialty consults, an ethics consultation, an attempt to transfer to another hospital service, and an attempt to transfer to another hospital before being able to cease futile medical interventions. It is important to note that these safeguards are necessary, but only because the government has failed to legislate a more streamlined process of ceasing futile care efforts.
While it is probably unsurprising that legislators have been wary to pick up such a hot-button political issue – particularly after the pillorying of “death panels” during recent healthcare debates – my greatest disappointment lies in lack of professional association’s attempts to fill the void. Although recommendations from professional groups like the Society of Critical Care Medicine or the American College of Physicians may not carry legal weight, such professional association guidelines are regularly used in medical malpractice cases to demonstrate whether a physician’s actions were considered “standard of care.” The issuing of such guidelines by professional organizations would provide the kind of backstop needed for physicians to more comfortably navigate ethical dilemmas like the one presented above. To date, the only national physician’s organization that has provided public recommendations for withdrawal of care is the American Society of Nephrology with a particular focus on withdrawal of dialysis for kidney failure. In the present political climate, further efforts to manage end-of-life care will need more physician and patient groups to publicly take a stand on what qualifies as appropriate care. Without such courageous steps, end-of-life care will become a further emotionally destructive and financially untenable part of our healthcare system.
Disclosure: I have no conflicts of interests with regard to end-of-life care and medically futile interventions.
Ira Leeds
Blue Oceans for Health 